<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of female genital tract bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of female genital tract bleeding</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of female genital tract bleeding</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew M Kaunitz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Females with abnormal bleeding noted in the genital area often present with a complaint of vaginal bleeding. Clinicians often attribute the bleeding to a uterine source, but it may arise from disease at any anatomic site in the lower genital tract (cervix, vagina, vulva) or upper genital tract (uterine corpus, fallopian tubes, ovaries). The source of bleeding may also be a nongynecologic site, such as the urethra, bladder, anus, or other bowel site. Causes of genital tract bleeding are listed in the table  (<a class="graphic graphic_table graphicRef74527" href="/d/graphic/74527.html" rel="external">table 1</a>) and vary by age group  (<a class="graphic graphic_table graphicRef61684" href="/d/graphic/61684.html" rel="external">table 2</a>).</p><p>Causes of female genital tract bleeding will be reviewed here. The evaluation of patients with vaginal bleeding is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonpregnant reproductive-age patients (see  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal patients (see  <a class="medical medical_review" href="/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant patients (see  <a class="medical medical_review" href="/d/html/6799.html" rel="external">"Evaluation and differential diagnosis of vaginal bleeding before 20 weeks of gestation"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adolescent patients (see  <a class="medical medical_review" href="/d/html/116.html" rel="external">"Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis"</a>).</p><p></p><p class="headingAnchor" id="H4036669841"><span class="h1">LOWER GENITAL TRACT SOURCES</span></p><p class="headingAnchor" id="H2986335202"><span class="h2">Cervical bleeding</span><span class="headingEndMark"> — </span>Bleeding from the cervix often causes sporadic spotting, which commonly occurs postcoitally. A cervical lesion is often visualized on speculum examination.</p><p class="headingAnchor" id="H2709677320"><span class="h3">Cervicitis</span><span class="headingEndMark"> — </span>Postcoital bleeding is common in patients with cervicitis due to nonspecific inflammatory changes or ulcerative sexually transmitted diseases. Strawberry red spots on the cervix with bleeding on contact are pathognomonic for Trichomonas vaginalis infection. (See  <a class="medical medical_review" href="/d/html/5460.html" rel="external">"Acute cervicitis"</a>.)</p><p class="headingAnchor" id="H2233886834"><span class="h3">Polyps</span><span class="headingEndMark"> — </span>Cervical polyps may cause postcoital spotting and sporadic bleeding, although they are often asymptomatic. The majority are benign endocervical polyps, which can be seen on visual examination of the cervix and endocervix. (See  <a class="medical medical_review" href="/d/html/5428.html" rel="external">"Benign cervical lesions and congenital anomalies of the cervix", section on 'Polyps'</a>.)</p><p class="headingAnchor" id="H350766818"><span class="h3">Ectropion</span><span class="headingEndMark"> — </span>Ectropion is the normal physiologic presence of endocervical glandular tissue on the exocervix. This tissue can be friable, readily bleeding upon contact, such as during intercourse or cervical cancer screening. (See  <a class="medical medical_review" href="/d/html/5428.html" rel="external">"Benign cervical lesions and congenital anomalies of the cervix", section on 'Ectropion'</a>.)</p><p class="headingAnchor" id="H833964213"><span class="h3">Pelvic organ prolapse</span><span class="headingEndMark"> — </span>Defects in pelvic floor support can lead to herniation of the anterior, posterior, or apical portion of the vagina. If part or all of the vagina and cervix is exteriorized, bleeding occasionally occurs secondary to ulceration, trauma and infection. This type of bleeding often occurs after straining. (See  <a class="medical medical_review" href="/d/html/8072.html" rel="external">"Pelvic organ prolapse in females: Epidemiology, risk factors, clinical manifestations, and management"</a>.)</p><p class="headingAnchor" id="H2829781679"><span class="h3">Trauma</span><span class="headingEndMark"> — </span>Bleeding can occur after both consensual sexual intercourse and sexual assault and may be the result of a cervical laceration. In one retrospective review including 114 sexual assault victims presenting to an acute care hospital, injuries to the cervix were found in 12 percent of patients [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4058649337"><span class="h3">Other benign conditions</span><span class="headingEndMark"> — </span>Ectopic endometriosis can be found in the cervix, especially if the patient has a history of cervical procedures (such as cone biopsy). Postcoital bleeding, intermenstrual bleeding, as well as acute bleeding due to cervical endometriosis have been reported [<a href="#rid2">2-4</a>]. (See  <a class="medical medical_review" href="/d/html/134970.html" rel="external">"Endometriosis: Clinical features, evaluation, and diagnosis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H2353298813"><span class="h3">Cervical cancer</span><span class="headingEndMark"> — </span>Sporadic bleeding, postcoital spotting, and vaginal discharge that is watery, mucoid, or purulent and malodorous are often noted in patients with cervical cancer. Accordingly, cervical cytology and biopsy, when indicated, should not be postponed in this setting. (See  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Direct extension from other pelvic tumors, such as uterine cancer, can cause cervical bleeding. Choriocarcinoma commonly can extend to the cervix, causing bleeding. Rarely, leukemias, lymphomas [<a href="#rid5">5</a>], and other nongynecologic cancers involve the cervix.</p><p class="headingAnchor" id="H4044306454"><span class="h2">Vaginal bleeding</span><span class="headingEndMark"> — </span>As with cervical lesions, vaginal lesions typically cause sporadic or postcoital bleeding and can be visualized on speculum examination. By contrast, traumatic vaginal lacerations can cause major internal and/or external hemorrhage.</p><p class="headingAnchor" id="H1254085816"><span class="h3">Vaginal atrophy</span><span class="headingEndMark"> — </span>Atrophic vaginitis results from estrogen deficient states, which occur in postmenopausal, postpartum lactating, and premenarchal patients. Bleeding or spotting, which may be related to sexual activity, may occur. (See  <a class="medical medical_review" href="/d/html/5464.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H1553034124"><span class="h3">Vaginitis and vaginal ulcers</span><span class="headingEndMark"> — </span>Vaginal infection or inflammation may lead to friability of the vaginal mucosa with bleeding. (See  <a class="medical medical_review" href="/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p>Ulcerative diseases with vaginal involvement (eg, lichen planus) can cause postcoital bleeding. Genital ulcers may be caused by infection, but non-infection-related etiologies should also be considered. (See  <a class="medical medical_review" href="/d/html/7592.html" rel="external">"Approach to the patient with genital ulcers"</a>.)</p><p class="headingAnchor" id="H2147612079"><span class="h3">Benign growths</span><span class="headingEndMark"> — </span>Gartner duct cysts, vaginal polyps, and aberrant glandular tissue (vaginal adenosis) rarely lead to vaginal bleeding in the absence of friction and trauma. (See  <a class="medical medical_review" href="/d/html/5417.html" rel="external">"Congenital anomalies of the hymen and vagina"</a>.)</p><p class="headingAnchor" id="H3898989775"><span class="h3">Vaginal trauma</span><span class="headingEndMark"> — </span>Bleeding from the vagina or vulva can occur from genital tract trauma related to intercourse (eg, tearing of an intact hymen during coitarche or laceration of the vaginal fornix mucosa), foreign bodies that cause ulceration (eg, neglected tampon, pessary, sexual aids), sexual assault, pelvic trauma (eg, from a motor vehicle accident), and straddle-type injuries (eg, falling on a bicycle frame, fence, or table edge) that result in lacerations or abrasions of the labia. (See  <a class="medical medical_review" href="/d/html/5449.html" rel="external">"Evaluation and management of female lower genital tract trauma"</a>.)</p><p>Female circumcision or infibulation reduces the vaginal opening; vaginal bleeding and lacerations can occur when intercourse is attempted. (See  <a class="medical medical_review" href="/d/html/3268.html" rel="external">"Female genital cutting"</a>.)</p><p class="headingAnchor" id="H144865293"><span class="h3">Toxic epidermal necrolysis and Stevens-Johnson syndrome</span><span class="headingEndMark"> — </span>Toxic epidermal necrolysis and Stevens-Johnson syndrome may be caused by a variety of drugs, particularly antibiotics. Vulvar and vaginal tissues are commonly involved in this acute and extensive destruction of the skin [<a href="#rid6">6</a>]. Bleeding may occasionally occur along with significant ulceration. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Mucosal involvement'</a>.)</p><p class="headingAnchor" id="H570853817"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Vaginal bleeding can represent a late effect of radiation therapy [<a href="#rid7">7</a>]. Obliterative endarteritis and the vascular narrowing of aging and arteriosclerosis lead to devascularization of the radiated tissues. Tissue necrosis causes viscus perforation, tissue sloughing, and bleeding. Hemorrhagic cystitis and proctitis can lead to significant blood loss. Vaginal vault necrosis may cause uncontrolled bleeding and pain. (See  <a class="medical medical_review" href="/d/html/90926.html" rel="external">"Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies"</a>.)</p><p class="headingAnchor" id="H2450349014"><span class="h3">Vaginal cancer</span><span class="headingEndMark"> — </span>Primary vaginal cancer is a less common gynecologic malignancy. The majority of patients present with vaginal bleeding, either postmenopausal or postcoital. Other symptoms include a watery, blood-tinged, or malodorous vaginal discharge or a vaginal mass. The upper posterior vaginal wall is the most frequent site of vaginal cancer. It is important to carefully palpate the lateral, anterior, and posterior vaginal walls since the lesion may be obscured by the speculum blades during examination [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/3221.html" rel="external">"Vaginal cancer"</a>.)</p><p>Advanced bladder or colorectal cancer may invade the vagina and cause vaginal bleeding [<a href="#rid9">9</a>], and the vagina may be the site of metastatic disease from distant organs.</p><p class="headingAnchor" id="H3033138605"><span class="h2">Vulvar bleeding</span><span class="headingEndMark"> — </span>As with cervical and vaginal lesions, vulvar lesions typically cause sporadic bleeding and can be visualized on physical examination.</p><p class="headingAnchor" id="H1770808916"><span class="h3">Infection</span><span class="headingEndMark"> — </span>Sexually transmitted diseases can cause characteristic lesions on the vulva, some of which may bleed easily on contact (friability). Examples include the syphilitic chancre (although this usually produces drainage that is more serous than bloody), herpes simplex virus, Haemophilus ducreyi (Chancroid), granuloma inguinale (Donovanosis), and lymphogranuloma venereum. Pediculosis pubis (ie, pubic lice or "crabs") can also cause a small amount of bleeding. (See  <a class="medical medical_review" href="/d/html/7592.html" rel="external">"Approach to the patient with genital ulcers"</a> and  <a class="medical medical_review" href="/d/html/4037.html" rel="external">"Pediculosis pubis and pediculosis ciliaris"</a>.)</p><p class="headingAnchor" id="H1303585090"><span class="h3">Benign lesions</span><span class="headingEndMark"> — </span>Benign lesions, such as sebaceous (epidermal) cysts, condylomata, and angiokeratoma, may occasionally bleed due to trauma related to friction from clothing or scratching. (See  <a class="medical medical_review" href="/d/html/5450.html" rel="external">"Vulvar lesions: Diagnostic evaluation"</a> and  <a class="medical medical_review" href="/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"</a>.)</p><p>Vulvar lichen sclerosus occasionally may result in bleeding and, rarely, hemorrhage. (See  <a class="medical medical_review" href="/d/html/5558.html" rel="external">"Vulvar lichen sclerosus: Clinical manifestations and diagnosis", section on 'Clinical manifestations and natural history'</a>.)</p><p class="headingAnchor" id="H4264084547"><span class="h3">Blistering and ulcerative diseases</span><span class="headingEndMark"> — </span>Bullous pemphigoid, cicatricial pemphigoid, epidermolysis bullosa acquisita, pemphigus vulgaris, and pemphigus vegetans are autoimmune blistering dermatologic disorders that can develop on the vulva. Erosions are usually seen due to the fragile nature of lesions and frictional trauma. Older lesions may be cloudy or hemorrhagic. Beçhet syndrome is a systemic vascular disorder that can cause genital ulcers. (See  <a class="medical medical_review" href="/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"</a>.)</p><p class="headingAnchor" id="H954293004"><span class="h3">Vulvar trauma</span><span class="headingEndMark"> — </span>The vulva may bleed from trauma due to forceful sexual activity/assault or accidents (eg, sports or exercise related, motor vehicle). (See  <a class="medical medical_review" href="/d/html/5449.html" rel="external">"Evaluation and management of female lower genital tract trauma"</a>.)</p><p class="headingAnchor" id="H2741977368"><span class="h3">Vulvar cancer</span><span class="headingEndMark"> — </span>Vulvar cancer is less common than other gynecologic malignancies. Early vulvar cancer is asymptomatic; bleeding occurs when a lesion is extensive enough to ulcerate.</p><p>Vulvar cancer and vulvar intraepithelial neoplasia are often misdiagnosed. Delay may be related to patient embarrassment, denial, reluctance to be examined, or health care practitioners who prescribe topical medications to a patient with vulvar complaints without performing a physical examination. All ulcers associated with skin thickening or mass must be biopsied. (See  <a class="medical medical_review" href="/d/html/3237.html" rel="external">"Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment"</a> and  <a class="medical medical_review" href="/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)"</a>.)</p><p>Vulvar melanoma presents with a hyperpigmented lesion, which may bleed. (See  <a class="medical medical_review" href="/d/html/16904.html" rel="external">"Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment", section on 'Vulvovaginal melanoma'</a>.)</p><p class="headingAnchor" id="H4185995232"><span class="h1">UPPER GENITAL TRACT SOURCES</span></p><p class="headingAnchor" id="H2"><span class="h2">Uterine bleeding</span><span class="headingEndMark"> — </span>The uterus is the most likely source of genital tract bleeding. The likelihood of a particular etiology of uterine bleeding depends on the reproductive status of the patient (premenarchal, reproductive-age, postmenopausal) and the pattern of bleeding (cyclic or noncyclic). The characteristics of normal and abnormal uterine bleeding (AUB) bleeding are listed in the table  (<a class="graphic graphic_table graphicRef103238" href="/d/graphic/103238.html" rel="external">table 3</a>) and are described in detail separately. (See  <a class="medical medical_review" href="/d/html/7418.html" rel="external">"Normal menstrual cycle", section on 'Definitions of normal uterine bleeding (menstruation)'</a> and  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Definitions'</a>.)</p><p>A revised terminology system for abnormal uterine bleeding (AUB) in nongravid reproductive-age patients was introduced in 2011 by the International Federation of Gynecology and Obstetrics (FIGO) [<a href="#rid10">10</a>]. This classification system, referred to as FIGO System 2, or the PALM-COEIN system, stratifies possible causes of AUB into nine basic categories: polyp, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, and not yet classified  (<a class="graphic graphic_figure graphicRef90483" href="/d/graphic/90483.html" rel="external">figure 1</a>). An example of a worksheet to facilitate documentation is found in the table  (<a class="graphic graphic_table graphicRef109662" href="/d/graphic/109662.html" rel="external">table 4</a>).  </p><p class="headingAnchor" id="H2837646682"><span class="h3">Polyps (AUB-P)</span><span class="headingEndMark"> — </span>Endometrial polyps are a common cause of AUB; most endometrial polyps are benign and the prevalence of endometrial polyps increases with age. Intermenstrual bleeding is the most frequent symptom, and bleeding after straining or heavy lifting can also occur. Less frequent symptoms include heavy or prolonged bleeding, postcoital bleeding, postmenopausal bleeding, prolapse through the cervical os, and unscheduled (breakthrough) bleeding during hormonal therapy. (See  <a class="medical medical_review" href="/d/html/5457.html" rel="external">"Endometrial polyps"</a>.)</p><p>A presumptive diagnosis can be made with imaging (eg, transvaginal ultrasound, sonohysterography, hysteroscopy); histopathologic confirmation is not required for AUB-P classification. (See  <a class="medical medical_review" href="/d/html/5457.html" rel="external">"Endometrial polyps", section on 'Pelvic imaging'</a> and  <a class="medical medical_review" href="/d/html/5457.html" rel="external">"Endometrial polyps", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H4233709953"><span class="h3">Adenomyosis (AUB-A)</span><span class="headingEndMark"> — </span>Adenomyosis, a disorder in which endometrial glands and stroma are present within the uterine myometrium, may result in a diffusely enlarged uterus and is often present in patients with uterine leiomyomas or endometriosis. However, the role that adenomyosis plays in the genesis of AUB is poorly understood, and data are conflicting regarding its association with heavy, prolonged, or painful menstrual periods [<a href="#rid11">11-15</a>]. (See  <a class="medical medical_review" href="/d/html/5489.html" rel="external">"Uterine adenomyosis"</a>.)</p><p>A presumptive diagnosis can be made based on transvaginal ultrasound or magnetic resonance imaging (MRI); histopathologic confirmation is not required for AUB-A classification. (See  <a class="medical medical_review" href="/d/html/5489.html" rel="external">"Uterine adenomyosis", section on 'Imaging'</a> and  <a class="medical medical_review" href="/d/html/5489.html" rel="external">"Uterine adenomyosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H753870829"><span class="h3">Leiomyomas (AUB-L)</span><span class="headingEndMark"> — </span>Leiomyomas (also referred to as myomas or fibroids) are the most common pelvic tumors in females. The majority of patients have small myomas and are asymptomatic; however many patients with leiomyomas have AUB. When leiomyomas are present, the uterus often feels enlarged and lobular/asymmetric on bimanual pelvic examination. </p><p>AUB-L is further classified based on the FIGO Leiomyoma Subclassification System  (<a class="graphic graphic_figure graphicRef91085" href="/d/graphic/91085.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history", section on 'Terminology and location'</a>.)</p><p>Uterine leiomyomas are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history"</a> and  <a class="medical medical_review" href="/d/html/5478.html" rel="external">"Uterine fibroids (leiomyomas): Treatment overview"</a>.)</p><p class="headingAnchor" id="H3798469613"><span class="h3">Malignancy and hyperplasia (AUB-M)</span><span class="headingEndMark"> — </span>Endometrial hyperplasia or cancer of the uterus may cause AUB. Subclassification is based on histology using the appropriate World Health Organization system for hyperplasia, or the FIGO staging system for cancer [<a href="#rid10">10,16-19</a>]. (See  <a class="medical medical_review" href="/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening"</a>.)</p><p>The risk of endometrial neoplasia increases with age and with exposure to endogenous or exogenous estrogen unopposed by a progestin (eg, obesity, anovulation, menopausal use of estrogen alone, or <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>). (See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention"</a> and  <a class="medical medical_review" href="/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding"</a>.)</p><p>Less common types of uterine cancer include uterine sarcomas (eg, endometrial stromal sarcoma, leiomyosarcoma) or gestational trophoblastic neoplasia. Rarely, the endometrium is the site of metastatic disease from a nongynecologic malignancy (eg, melanoma).</p><p>(See  <a class="medical medical_review" href="/d/html/3211.html" rel="external">"Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/95881.html" rel="external">"Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification"</a>.)</p><p class="headingAnchor" id="H1634903642"><span class="h3">Coagulopathy (AUB-C)</span><span class="headingEndMark"> — </span>Bleeding disorders can cause AUB, usually heavy menstrual bleeding (HMB). The approach to identifying these patients starts with a structured history to assess symptoms or risk factors for coagulation disorders  (<a class="graphic graphic_table graphicRef90289" href="/d/graphic/90289.html" rel="external">table 5</a>) [<a href="#rid20">20</a>]. Laboratory testing must confirm coagulopathy for a diagnosis of AUB-C. </p><p>Bleeding disorders are common in reproductive-age patients. Up to 15 to 29 percent of patients presenting with HMB may have some type of bleeding diathesis (eg, von Willebrand disease [VWD], immune thrombocytopenia, or platelet function defect) [<a href="#rid20">20-22</a>]. In one series including patients ages 18 to 45, bleeding disorders were diagnosed in 11 percent of patients with HMB (VWD [8/121], factor deficiencies [2/121], platelet abnormality [3/121]) but only 3 percent of patients with normal menstrual cycles [<a href="#rid23">23</a>]. Systematic reviews of HMB report an even higher prevalence of VWD (range 5 to 24 percent) [<a href="#rid24">24,25</a>]. However, the percentage of HMB attributable solely to VWD is not clear as many such patients also have uterine pathology, which may be exacerbated by the underlying coagulopathy [<a href="#rid26">26</a>].</p><p>In patients with VWD, the menopausal transition is associated with an increased prevalence of excess bleeding due to decreasing estrogen levels. Estrogen promotes von Willebrand factor (VWF) synthesis. Conversely, patients with mild VWD who take birth control pills or menopausal estrogen therapy may increase their slightly low VWF levels into the normal range and, during pregnancy, VWF levels also increase. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Changes with aging and pregnancy'</a>.)</p><p>Bleeding defects may also be due to renal failure (platelet dysfunction), liver disease (reduced synthesis of coagulation factors), hematologic malignancy [<a href="#rid27">27</a>], anticoagulants, or chemotherapeutic agents. (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Patient history'</a>.)</p><p>AUB due to bleeding disorders is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder", section on 'Patient history'</a> and  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Medical history'</a> and  <a class="medical medical_review" href="/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency", section on 'Heavy menstrual bleeding'</a>.)</p><p class="headingAnchor" id="H1606850401"><span class="h3">Ovulatory dysfunction (AUB-O)</span><span class="headingEndMark"> — </span>AUB-O includes anovulation and oligo-ovulation and is a common cause of AUB in nonpregnant reproductive-age patients. Etiologies that may result in ovulatory dysfunction are presented in the table  (<a class="graphic graphic_table graphicRef79628" href="/d/graphic/79628.html" rel="external">table 6</a>). AUB-O is not used to classify ovulatory dysfunction caused by drug treatment, which are classified as AUB-I (iatrogenic causes). (See <a class="local">'Iatrogenic causes (AUB-I)'</a> below.) </p><p>AUB-O can be further categorized according to the presumed primary source (and referred to by the acronym "HyPO-P") [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Type I: <strong>Hy</strong>pothalamic</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type II: <strong>P</strong>ituitary</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type III: <strong>O</strong>varian</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type IV: <strong>P</strong>COS </p><p></p><p>The pathophysiology in patients with AUB-O is that sex steroids are not produced cyclically. In many anovulatory patients, estrogen production unopposed by adequate progesterone production allows continued proliferation of the endometrium. Eventually, the thickened endometrium outgrows its blood supply and undergoes focal necrosis with partial shedding. Since shedding is not uniform and progesterone and prostaglandin-related changes have not occurred, bleeding is usually irregular (varies by &gt;7 to 9 days, depending on age) and can be prolonged and/or heavy (see  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Definitions'</a>). In patients with oligo-ovulation, some episodes of bleeding represent partial endometrial shedding and others are normal (postovulatory) menses.</p><p>Common causes of anovulation by patient age include:</p><p class="bulletIndent1"><span class="glyph">●</span>For a few years following menarche, the hypothalamic-pituitary-ovarian axis is not fully mature and ovulatory cycles may not consistently occur. Thus, amenorrhea or infrequent menses may alternate with unpredictable episodes of uterine bleeding. Less commonly, AUB in this age group may be related to other causes, such as pregnancy or a coagulopathy. (See  <a class="medical medical_review" href="/d/html/116.html" rel="external">"Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis", section on 'Causes of vaginal bleeding in adolescents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In reproductive-age patients, polycystic ovary syndrome (PCOS) is a common cause of anovulation. AUB associated with PCOS is characterized by chronic unopposed estrogen stimulation of the endometrium with irregular shedding. The presence of irregular menstrual cycles (often infrequent bleeding episodes), hirsutism, acne, acanthosis nigricans, as well as (when applicable) characteristic ovarian changes on ultrasound should lead clinicians to suspect this diagnosis. (See  <a class="medical medical_review" href="/d/html/7430.html" rel="external">"Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"</a> and  <a class="medical medical_review" href="/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During the menopausal transition, patients commonly experience intermittent episodes of anovulatory bleeding, heavy or prolonged periods, and hot flashes related to fluctuations in hypothalamic-pituitary-ovarian axis function that accompanies the natural decline in ovarian follicles [<a href="#rid29">29,30</a>]. Such patients are also more likely than younger patients to have bleeding related to benign or malignant neoplasms (eg, leiomyomas, endometrial polyps, endometrial carcinoma). (See  <a class="medical medical_review" href="/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause"</a>.)</p><p></p><p>Other causes of AUB-O include: </p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid disease. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Genitourinary'</a> and  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Reproductive abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperprolactinemia  (<a class="graphic graphic_table graphicRef75914" href="/d/graphic/75914.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stress and poor nutrition: Stress, weight loss, poor nutrition, or strenuous exercise can disturb the hypothalamic-pituitary-ovarian axis and may cause AUB. Although the menstrual pattern most characteristic of hypothalamic dysfunction is amenorrhea, some patients with this entity may present with infrequent (ie, &gt;38 day) cycles. (See  <a class="medical medical_review" href="/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/104135.html" rel="external">"Epidemiology and causes of secondary amenorrhea", section on 'Hypothalamic dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cushing syndrome. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Menstrual irregularities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hormone-producing ovarian (eg, granulosa cell tumor) or adrenal tumors (rare). (See  <a class="medical medical_review" href="/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver and kidney disease: Liver disease can affect estrogen metabolism, synthesis of coagulation factors, and cause thrombocytopenia, thereby potentially leading to both anovulation and bleeding diathesis. Chronic renal disease is associated with both hypothalamic-pituitary-gonadal and platelet dysfunction. (See <a class="local">'Coagulopathy (AUB-C)'</a> above.)</p><p></p><p>The evaluation of patients with AUB-O is discussed separately. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Irregular bleeding'</a>.)</p><p class="headingAnchor" id="H1323624457"><span class="h3">Endometrial dysfunction (AUB-E)</span><span class="headingEndMark"> — </span>Patients with AUB-E have <strong>all</strong> of the following [<a href="#rid31">31</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Predictable and cyclic menses suggestive of normal ovulation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HMB or intermenstrual bleeding</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No other definable causes for AUB </p><p></p><p>AUB-E is primarily caused by disturbances in the molecular and cellular mechanisms responsible for regulation of the volume of blood lost at menstruation. Inflammatory or infectious endometrial disorders, such as endometritis or pelvic inflammatory disease (PID) are also included in this category:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local endometrial hemostasis disorders</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombolysis</strong> – In ovulatory menstrual cycles, progesterone stabilizes the endometrium and prevents unscheduled bleeding by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Blocking stromal cell production of matrix metalloproteinase (MMP) 1, 3, and 9, which degrade the extravascular and stromal matrix [<a href="#rid32">32,33</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stimulating stromal cell production of tissue factor (TF), a cell surface protein that participates in the extrinsic pathway of coagulation through the binding of activated Factor VII [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stimulating stroma cell production of plasminogen activator inhibitor 1 (PAI-1), which blocks fibrinolysis, thereby stabilizing clots [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2">In anovulatory menstrual cycles, the absence of a regular cyclical progesterone stimulus results in excessive production of MMP 1, 3, and 9, decreased production of TF and PAI-1, thereby leading to unpredictable menstrual bleeding in both timing and amount. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prostaglandins</strong> – Patients with HMB may have increased expression of cyclooxygenases (COX-1, COX-2) and increased endometrial responsiveness to stimulation by prostaglandins [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory or infectious endometrial disorders </strong>– Infection and inflammation (endometritis or PID) can result in AUB. Endometritis may be acute (pregnancy-related or unrelated to pregnancy) or chronic. (See  <a class="medical medical_review" href="/d/html/5488.html" rel="external">"Postpartum endometritis"</a> and  <a class="medical medical_review" href="/d/html/5462.html" rel="external">"Endometritis unrelated to pregnancy"</a>.)</p><p></p><p class="bulletIndent1">Etiologies may include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Chlamydia trachomatis</em> [<a href="#rid31">31,37</a>] or PID. In a series of 70 patients (median age 24 years, range 16 to 45 years) with possible upper genital tract infection, 15 presented with AUB, underscoring that endometritis associated with PID can present with this symptom [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Instrumentation following an intrauterine procedure, including placement of an intrauterine contraceptive (uncommon). (See  <a class="medical medical_review" href="/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications", section on 'Infection and/or pelvic inflammatory disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy and/or cervical stenosis – Underlying endometrial cancer in postmenopausal patients may also cause endometritis. In the setting of cervical stenosis, blood can accumulate in the uterus (hematometra) and become secondarily infected (pyometra).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inflammation of neighboring organs, such as diverticulitis, can occasionally cause corresponding inflammation of the female upper genital tract. A ruptured sigmoid diverticulum may fistulize into the uterus and present as uterine bleeding, discharge, and endometritis.</p><p></p><p class="headingAnchor" id="H2624267327"><span class="h3">Iatrogenic causes (AUB-I)</span><span class="headingEndMark"> — </span>Iatrogenic causes of AUB include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraception</strong> –<strong> </strong>Contraceptive methods that can cause abnormal vaginal bleeding include estrogen-progestin contraceptives, progestin-only contraceptives, and intrauterine devices (IUD). (See  <a class="medical medical_review" href="/d/html/5474.html" rel="external">"Evaluation and management of unscheduled bleeding in individuals using hormonal contraception"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Estrogen-progestin contraceptives – Breakthrough (or unscheduled) bleeding is the most common side effect of combination hormonal contraceptives. This reflects tissue breakdown as the endometrium adjusts to a new thin state in which it is fragile and atrophic. Patients should be cautioned that missing pills results in an increase in unscheduled bleeding, as well as a decrease in contraceptive efficacy. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Unscheduled bleeding'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progestin-only contraceptives – Prolonged bleeding and spotting are common side effects of progestin-only contraceptives, including depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>, the levonorgestrel-releasing intrauterine contraceptive, etonogestrel single contraceptive implant systems, and progestin-only pills. Bleeding tends to be an early side effect of these methods; many patients develop amenorrhea with continued use. The mechanism of progesterone-breakthrough bleeding is endometrial atrophy due to insufficient estrogen. (See  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a> and  <a class="medical medical_review" href="/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a> and  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a> and  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Copper IUD – <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">Copper IUDs</a> cause a foreign body reaction in the uterus that creates an inflammatory response. The endometrium may hypertrophy at the site of inflammation with normal cyclic estrogen stimulation, resulting in heavier or longer menstrual flow as well as intermenstrual bleeding. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Copper IUD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Menopausal HT</strong> –<strong> </strong>Patients who use menopausal hormone therapy (HT) may develop uterine bleeding; the frequency depends upon the regimen used, and whether uterine conditions including fibroids, adenomyosis, or endometrial polyps are present. (See  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulants</strong>. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> –<strong> </strong>Medications that cause an endocrine disruption may cause AUB. Some data suggest that epidural glucocorticoid injections (40 to 80 mg of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> or <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> acetate) are associated with AUB [<a href="#rid39">39</a>]. Drugs that cause hyperprolactinemia are shown in the table  (<a class="graphic graphic_table graphicRef75914" href="/d/graphic/75914.html" rel="external">table 7</a>). (See <a class="local">'Ovulatory dysfunction (AUB-O)'</a> above and  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>.)</p><p></p><p class="headingAnchor" id="H4105812903"><span class="h3">Not otherwise classified (AUB-N)</span><span class="headingEndMark"> — </span>AUB-N encompasses additional entities that may cause AUB and include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cesarean scar defect </strong>–<strong> </strong>A cesarean scar defect (also known as an isthmocele or niche) at the site of a prior hysterotomy (or less commonly, myomectomy) incision is an increasingly common cause of AUB [<a href="#rid40">40-46</a>]. The usual presentation is postmenstrual spotting, which may reflect intermittent expulsion of menstrual blood retained in the defect after menstruation is completed. Poor contractility of the myometrium in the area of the hysterotomy site may also contribute to postmenstrual spotting [<a href="#rid47">47</a>]. When symptoms (eg, postmenstrual bleeding) are present, the term "cesarean scar disorder" may be used [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent1">In a prospective study including over 370 patients evaluated with sonohysterography six months after cesarean birth, patients with (46 percent) versus without a cesarean scar defect were more likely to have postmenstrual spotting (20 versus 8 percent, odds ratio [OR] 2.8, 95% CI 1.4-5.4) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arteriovenous malformation</strong> – Arteriovenous malformation (AVM) of the uterus is a rare cause of AUB in which arteries and veins directly connect, rather than going through capillaries [<a href="#rid50">50,51</a>]. Direct connection of these vessels results in enlarged, tangled-appearing vascular structures with turbulent flow. AVM has been variably described as a cirsoid aneurysm, arteriovenous aneurysm, arteriovenous fistula, and cavernous hemangioma. </p><p></p><p class="bulletIndent1">Some AVMs are acquired and present with sudden uterine bleeding after surgical instrumentation (eg, dilation and curettage in a nonpregnant patient), while others are congenital and occur without any prior history of surgical instrumentation  (<a class="graphic graphic_diagnosticimage graphicRef54928" href="/d/graphic/54928.html" rel="external">image 1</a>) [<a href="#rid50">50,51</a>]. Congenital AVMs are thought to develop from a failure of embryologic differentiation leading to abnormal vascular connections [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">If an AVM is suspected in a patient with AUB, imaging studies should be performed prior to further intrauterine instrumentation [<a href="#rid53">53</a>]. Pelvic ultrasound with Doppler is typically the first-line imaging study  (<a class="graphic graphic_diagnosticimage graphicRef131946" href="/d/graphic/131946.html" rel="external">image 2</a>) [<a href="#rid54">54-56</a>]. MRI with angiography may also be performed.</p><p></p><p class="bulletIndent1">AUB related to an AVM may be refractory to hormonal management. Management of patients with AVMs and AUB is discussed separately. (See  <a class="medical medical_review" href="/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Structural lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced myometrial vascularity</strong> – It is important to different AVM from enhanced myometrial vascularity (EMV), which is its own diagnostic entity and usually occurs in the setting of retained products of conception following delivery (presenting as delayed postpartum hemorrhage) or pregnancy loss/termination (all trimesters)  (<a class="graphic graphic_diagnosticimage graphicRef139474" href="/d/graphic/139474.html" rel="external">image 3</a>) [<a href="#rid57">57,58</a>]. As the use of vaginal ultrasound with Doppler assessment of uterine vascularity is becoming more widespread, the diagnosis of EMV is increasing.</p><p></p><p class="bulletIndent1">Management of patients with EMV is with expectant management or dilation and curettage; this is distinct from those with AVM and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5482.html" rel="external">"Retained products of conception in the first half of pregnancy", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/113133.html" rel="external">"Secondary (late) postpartum hemorrhage", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> –<strong> </strong>Rarely, sarcoidosis affects the female genital tract and the uterus is the most common site [<a href="#rid59">59</a>]. Patients with uterine sarcoidosis may present with AUB. Most patients have concomitant pulmonary involvement. (See  <a class="medical medical_review" href="/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis"</a>.)</p><p></p><p class="headingAnchor" id="H62914140"><span class="h2">Fallopian tube bleeding</span><span class="headingEndMark"> — </span>Blood from the fallopian tube may rarely pass through the uterus and present as vaginal bleeding. However, this is unusual and most fallopian tube bleeding presents as intraperitoneal bleeding. Etiologies of fallopian tube bleeding include tubal pregnancy, neoplastic disease, trauma, and infection.</p><p class="headingAnchor" id="H2911413900"><span class="h3">Salpingitis</span><span class="headingEndMark"> — </span>Salpingitis is generally not an isolated infection but is usually associated with PID. In patients with PID, the source of bleeding may be the uterus or the fallopian tube. (See <a class="local">'Endometrial dysfunction (AUB-E)'</a> above.)</p><p class="headingAnchor" id="H3762169867"><span class="h3">Hysteroscopic sterilization</span><span class="headingEndMark"> — </span>A dislodged tubal microinsert may result in bleeding [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/3277.html" rel="external">"Hysteroscopic female permanent contraception", section on 'Short-term complications and outcomes'</a>.)</p><p class="headingAnchor" id="H1196041007"><span class="h3">Fallopian tube cancer</span><span class="headingEndMark"> — </span>Fallopian tube cancer may also present with vaginal bleeding. (See <a class="local">'Ovarian cancer'</a> below and  <a class="medical medical_review" href="/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis", section on 'Vaginal bleeding'</a>.)</p><p class="headingAnchor" id="H4068508779"><span class="h2">Ovarian bleeding</span><span class="headingEndMark"> — </span>Similar to bleeding from the fallopian tube, bleeding from the ovary rarely presents as vaginal bleeding and more commonly presents as intraperitoneal bleeding (eg, a bleeding corpus luteum, which may occur in anticoagulated patients). Infrequently, bleeding from an ovarian mass, trauma, or infection may pass through the fallopian tube and continue to the lower genital tract.</p><p class="headingAnchor" id="H1100835888"><span class="h3">Ovarian cancer</span><span class="headingEndMark"> — </span>Vaginal bleeding represents an uncommon presentation of ovarian cancer [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis", section on 'Vaginal bleeding'</a>.)</p><p class="headingAnchor" id="H47"><span class="h1">NONGENITAL TRACT DISEASE</span><span class="headingEndMark"> — </span>Diseases of the tissue and organs surrounding the female genital tract may initially be mistaken for genital tract bleeding; nongenital tract sources include: urethra (eg, urethritis, diverticulum, urethral prolapse or caruncle, or atrophy), bladder (eg, cancer, stone, or infection), anus (eg, hemorrhoids, anal cancer), bowel (eg, inflammatory bowel disease, rectal cancer), or dermatologic conditions of the perineum or skin beyond the vulva. (See  <a class="medical medical_review" href="/d/html/5430.html" rel="external">"Urethral caruncle"</a> and  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'Gynecologic and obstetric history'</a>.)</p><p class="headingAnchor" id="H1049493304"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H23757662"><span class="h2">Children</span><span class="headingEndMark"> — </span>Common causes of vaginal bleeding prior to menarche include vaginal foreign bodies (eg, toilet paper, pencil erasers), urethral prolapse, bacterial infections, trauma (including sexual assault), and condyloma. Less commonly, bleeding may result from a reproductive tract neoplasm, such as sarcoma botryoides. (See  <a class="medical medical_review" href="/d/html/15411.html" rel="external">"Evaluation of vulvovaginal bleeding in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/6450.html" rel="external">"Overview of vulvovaginal conditions in the prepubertal child"</a>.)</p><p class="headingAnchor" id="H139235090"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>Bleeding from the vagina is a common event at all stages of pregnancy; the source is virtually never fetal. Causes of vaginal bleeding in pregnant patients are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6799.html" rel="external">"Evaluation and differential diagnosis of vaginal bleeding before 20 weeks of gestation"</a>.)</p><p>Vaginal bleeding is also a common presentation of ectopic pregnancy; in such patients, the presumptive source of this bleeding is sloughing of the decidualized endometrium rather than bleeding from the tube itself [<a href="#rid63">63,64</a>]. While the fallopian tube is the most common site of ectopic pregnancy, other sites of extrauterine gestations include the abdomen, ovary, or cervix. Cesarean scar pregnancies can also occur. (See  <a class="medical medical_review" href="/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Vaginal bleeding'</a> and  <a class="medical medical_review" href="/d/html/5481.html" rel="external">"Ectopic pregnancy: Epidemiology, risk factors, and anatomic sites", section on 'Anatomic sites'</a>.)</p><p class="headingAnchor" id="H639230928"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109362.html" rel="external">"Society guideline links: Abnormal uterine bleeding"</a>.)</p><p class="headingAnchor" id="H48"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8401.html" rel="external">"Patient education: Abnormal uterine bleeding (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/8405.html" rel="external">"Patient education: Heavy or prolonged menstrual bleeding (menorrhagia) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2184.html" rel="external">"Patient education: Absent or irregular periods (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H49"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources</strong> – Females with abnormal bleeding noted in the genital area often present with a complaint of vaginal bleeding. Clinicians often attribute the bleeding to a uterine source, but it may arise from disease at any anatomic site in the lower genital tract (cervix, vagina, vulva) or upper genital tract (uterine corpus, fallopian tubes, ovaries). The source of bleeding may also be a nongynecologic site, such as the urethra, bladder, anus, or other bowel site  (<a class="graphic graphic_table graphicRef74527" href="/d/graphic/74527.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef61684" href="/d/graphic/61684.html" rel="external">table 2</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower genital tract sources</strong> –<strong> </strong>Causes of cervical, vaginal, and vulvar bleeding include trauma, infection, neoplasia, and genital manifestations of systemic disease. Bleeding from these areas<strong> </strong>often causes sporadic or postcoital bleeding, but hemorrhage can occur. A lesion is often visualized on examination. (See <a class="local">'Cervical bleeding'</a> above and <a class="local">'Vaginal bleeding'</a> above and <a class="local">'Vulvar bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper genital tract sources</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uterus</strong> – The uterus is the most likely source of genital tract bleeding. The etiology of uterine bleeding depends on the reproductive status of the patient (premenarchal, reproductive-age, postmenopausal) and the pattern of bleeding (cyclic or noncyclic). Possible causes of abnormal uterine bleeding (AUB) are divided into nine basic categories: polyp, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, and not yet classified  (<a class="graphic graphic_figure graphicRef90483" href="/d/graphic/90483.html" rel="external">figure 1</a>). (See <a class="local">'Uterine bleeding'</a> above.)</p><p></p><p class="bulletIndent2">Uterine bleeding is also a common event at all stages of pregnancy; the source is virtually never fetal. Ectopic pregnancy must also be considered. (See <a class="local">'Pregnant patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fallopian tube</strong> – Fallopian tube bleeding may rarely present as vaginal bleeding. Etiologies of fallopian tube bleeding include ectopic pregnancy and salpingitis, typically as part of pelvic inflammatory disease. (See <a class="local">'Fallopian tube bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ovary</strong> – Although bleeding from the ovary usually collects intraperitoneally, vaginal bleeding may occur if blood passes through the fallopian tube and continues to the lower genital tract. Etiologies of ovarian bleeding include benign neoplasms and ovarian cancer. (See <a class="local">'Ovarian bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nongenital tract bleeding</strong> – Diseases of the urethra (eg, urethritis, diverticulum), bladder (eg, cancer, stone, infection), and bowel (eg, inflammatory bowel disease, hemorrhoids) may cause bleeding that is misdiagnosed as genital tract bleeding. (See <a class="local">'Nongenital tract disease'</a> above.)</p><p></p><p class="headingAnchor" id="H14753346"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Annekathryn Goodman, MD, MPH, MS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Keller P, Lechner M. Injuries to the cervix in sexual assault victims. J Forensic Nurs 2010; 6:196.</a></li><li><a class="nounderline abstract_t">Seval MM, Cavkaytar S, Atak Z, Guresci S. Postcoital bleeding due to cervical endometriosis. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Wang S, Li XC, Lang JH. Cervical endometriosis: clinical character and management experience in a 27-year span. Am J Obstet Gynecol 2011; 205:452.e1.</a></li><li><a class="nounderline abstract_t">Mendoza GO, Castañón FJ, Hernández M, et al. [Deep cervical endometriosis causing profuse vaginal bleeding. Case report and literature review]. Ginecol Obstet Mex 2009; 77:518.</a></li><li><a class="nounderline abstract_t">Wilkie GL, Taggart AA, Prensner JR, et al. Burkitt Lymphoma Presenting as Menorrhagia and a Vaginal Mass in an Adolescent. J Pediatr Adolesc Gynecol 2019; 32:90.</a></li><li><a class="nounderline abstract_t">Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91:283.</a></li><li class="breakAll">Hopewell JW. The importance of vascular damage in the development of late radiation effects of normal tissues. In: Radiation Biology in Cancer Research, Meyn RE, Withers HR (Eds), Raven Press, New York 1980. p.449.</li><li><a class="nounderline abstract_t">Al-Kurdi M, Monaghan JM. Thirty-two years experience in management of primary tumours of the vagina. Br J Obstet Gynaecol 1981; 88:1145.</a></li><li><a class="nounderline abstract_t">Brand A, Scurry J, Planner R, Leung S. Primary and recurrent colorectal cancer masquerading as gynaecological malignancy. Aust N Z J Obstet Gynaecol 1996; 36:165.</a></li><li><a class="nounderline abstract_t">Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011; 113:3.</a></li><li><a class="nounderline abstract_t">Weiss G, Maseelall P, Schott LL, et al. Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health Across the Nation (SWAN). Fertil Steril 2009; 91:201.</a></li><li><a class="nounderline abstract_t">Naftalin J, Hoo W, Pateman K, et al. Is adenomyosis associated with menorrhagia? Hum Reprod 2014; 29:473.</a></li><li><a class="nounderline abstract_t">Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997; 68:426.</a></li><li><a class="nounderline abstract_t">Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76:195.</a></li><li><a class="nounderline abstract_t">Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009; 79:189.</a></li><li><a class="nounderline abstract_t">Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet 2018; 143:393.</a></li><li><a class="nounderline abstract_t">Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. Corrigendum to "The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions" [Int J Gynecol Obstet 143(2018) 393-408.]. Int J Gynaecol Obstet 2019; 144:237.</a></li><li class="breakAll">Tavassoli FA, Devilee P. orld Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, IARC Press, Lyon 2003.</li><li><a class="nounderline abstract_t">Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet 2018; 143 Suppl 2:37.</a></li><li><a class="nounderline abstract_t">Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351:485.</a></li><li><a class="nounderline abstract_t">Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145:212.</a></li><li><a class="nounderline abstract_t">Knol HM, Mulder AB, Bogchelman DH, et al. The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. Am J Obstet Gynecol 2013; 209:202.e1.</a></li><li><a class="nounderline abstract_t">Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97:630.</a></li><li><a class="nounderline abstract_t">Shankar M, Lee CA, Sabin CA, et al. von Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004; 111:734.</a></li><li><a class="nounderline abstract_t">James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: a systematic review. Obstet Gynecol 2004; 104:381.</a></li><li><a class="nounderline abstract_t">Kouides PA, Conard J, Peyvandi F, et al. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril 2005; 84:1345.</a></li><li><a class="nounderline abstract_t">Nebgen DR, Rhodes HE, Hartman C, et al. Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. Obstet Gynecol 2016; 128:357.</a></li><li><a class="nounderline abstract_t">Munro MG, Balen AH, Cho S, et al. The FIGO ovulatory disorders classification system. Int J Gynaecol Obstet 2022; 159:1.</a></li><li><a class="nounderline abstract_t">Donnez J. Menometrorrhagia during the premenopause: an overview. Gynecol Endocrinol 2011; 27 Suppl 1:1114.</a></li><li><a class="nounderline abstract_t">Berga SL. Disordered folliculogenesis during the menopausal transition: explaining chaos. Menopause 2009; 16:11.</a></li><li><a class="nounderline abstract_t">American Collegeof Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: number 41, December 2002. Obstet Gynecol 2002; 100:1389.</a></li><li><a class="nounderline abstract_t">Grzechocinska B, Dabrowski FA, Chlebus M, et al. Expression of matrix metalloproteinase enzymes in endometrium of women with abnormal uterine bleeding. Neuro Endocrinol Lett 2018; 38:537.</a></li><li><a class="nounderline abstract_t">Galant C, Berlière M, Dubois D, et al. Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am J Pathol 2004; 165:83.</a></li><li><a class="nounderline abstract_t">Liu X, Nie J, Guo SW. Elevated immunoreactivity to tissue factor and its association with dysmenorrhea severity and the amount of menses in adenomyosis. Hum Reprod 2011; 26:337.</a></li><li><a class="nounderline abstract_t">Nordengren J, Pilka R, Noskova V, et al. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle. Mol Hum Reprod 2004; 10:655.</a></li><li><a class="nounderline abstract_t">Smith OP, Jabbour HN, Critchley HO. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 2007; 22:1450.</a></li><li><a class="nounderline abstract_t">Toth M, Patton DL, Esquenazi B, et al. Association between Chlamydia trachomatis and abnormal uterine bleeding. Am J Reprod Immunol 2007; 57:361.</a></li><li><a class="nounderline abstract_t">Peipert JF, Boardman LA, Sung CJ. Performance of clinical and laparoscopic criteria for the diagnosis of upper genital tract infection. Infect Dis Obstet Gynecol 1997; 5:291.</a></li><li><a class="nounderline abstract_t">Suh-Burgmann E, Hung YY, Mura J. Abnormal vaginal bleeding after epidural steroid injection: a paired observation cohort study. Am J Obstet Gynecol 2013; 209:206.e1.</a></li><li><a class="nounderline abstract_t">Tower AM, Frishman GN. Cesarean scar defects: an underrecognized cause of abnormal uterine bleeding and other gynecologic complications. J Minim Invasive Gynecol 2013; 20:562.</a></li><li><a class="nounderline abstract_t">Tahara M, Shimizu T, Shimoura H. Preliminary report of treatment with oral contraceptive pills for intermenstrual vaginal bleeding secondary to a cesarean section scar. Fertil Steril 2006; 86:477.</a></li><li><a class="nounderline abstract_t">Monteagudo A, Carreno C, Timor-Tritsch IE. Saline infusion sonohysterography in nonpregnant women with previous cesarean delivery: the "niche" in the scar. J Ultrasound Med 2001; 20:1105.</a></li><li><a class="nounderline abstract_t">Fabres C, Arriagada P, Fernández C, et al. Surgical treatment and follow-up of women with intermenstrual bleeding due to cesarean section scar defect. J Minim Invasive Gynecol 2005; 12:25.</a></li><li><a class="nounderline abstract_t">Van Horenbeeck A, Temmerman M, Dhont M. Cesarean scar dehiscence and irregular uterine bleeding. Obstet Gynecol 2003; 102:1137.</a></li><li><a class="nounderline abstract_t">Thurmond AS, Harvey WJ, Smith SA. Cesarean section scar as a cause of abnormal vaginal bleeding: diagnosis by sonohysterography. J Ultrasound Med 1999; 18:13.</a></li><li><a class="nounderline abstract_t">Reiter M, Schwope R. Finding a niche: Magnetic resonance imaging located an often-overlooked source of uterine bleeding. Am J Obstet Gynecol 2014; 210:171.e1.</a></li><li><a class="nounderline abstract_t">Bij de Vaate AJ, Brölmann HA, van der Voet LF, et al. Ultrasound evaluation of the Cesarean scar: relation between a niche and postmenstrual spotting. Ultrasound Obstet Gynecol 2011; 37:93.</a></li><li><a class="nounderline abstract_t">Klein Meuleman SJM, Murji A, van den Bosch T, et al. Definition and Criteria for Diagnosing Cesarean Scar Disorder. JAMA Netw Open 2023; 6:e235321.</a></li><li><a class="nounderline abstract_t">Antila RM, Mäenpää JU, Huhtala HS, et al. Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study. Eur J Obstet Gynecol Reprod Biol 2020; 244:134.</a></li><li><a class="nounderline abstract_t">Ghai S, Rajan DK, Asch MR, et al. Efficacy of embolization in traumatic uterine vascular malformations. J Vasc Interv Radiol 2003; 14:1401.</a></li><li><a class="nounderline abstract_t">Fleming H, Ostör AG, Pickel H, Fortune DW. Arteriovenous malformations of the uterus. Obstet Gynecol 1989; 73:209.</a></li><li><a class="nounderline abstract_t">Kasznica J, Nisar N. Congenital vascular malformation of the uterus in a stillborn: a case report. Hum Pathol 1995; 26:240.</a></li><li><a class="nounderline abstract_t">Badawy SZ, Etman A, Singh M, et al. Uterine artery embolization: the role in obstetrics and gynecology. Clin Imaging 2001; 25:288.</a></li><li><a class="nounderline abstract_t">Nasu K, Fujisawa K, Yoshimatsu J, Miyakawa I. Uterine arteriovenous malformation: ultrasonographic, magnetic resonance and radiological findings. Gynecol Obstet Invest 2002; 53:191.</a></li><li><a class="nounderline abstract_t">Huang MW, Muradali D, Thurston WA, et al. Uterine arteriovenous malformations: gray-scale and Doppler US features with MR imaging correlation. Radiology 1998; 206:115.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Haynes MC, Monteagudo A, et al. Ultrasound diagnosis and management of acquired uterine enhanced myometrial vascularity/arteriovenous malformations. Am J Obstet Gynecol 2016; 214:731.e1.</a></li><li><a class="nounderline abstract_t">Groszmann YS, Healy Murphy AL, Benacerraf BR. Diagnosis and management of patients with enhanced myometrial vascularity associated with retained products of conception. Ultrasound Obstet Gynecol 2018; 52:396.</a></li><li><a class="nounderline abstract_t">Mimura K, Endo M, Kakigano A, et al. Sonographic findings after induced medical abortion at 12-21 weeks of gestation: Retrospective cohort study. Contraception 2020; 102:87.</a></li><li><a class="nounderline abstract_t">Marak CP, Alappan N, Chopra A, et al. Uterine sarcoidosis: a rare extrapulmonary site of sarcoidosis. Case Rep Rheumatol 2013; 2013:706738.</a></li><li><a class="nounderline abstract_t">Booker CJ, Yarwood RL, Dodson WC. Dislodged Essure microinsert. Fertil Steril 2008; 89:964.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 2011; 344:d8009.</a></li><li><a class="nounderline abstract_t">Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009; 339:b2998.</a></li><li><a class="nounderline abstract_t">Crochet JR, Bastian LA, Chireau MV. Does this woman have an ectopic pregnancy?: the rational clinical examination systematic review. JAMA 2013; 309:1722.</a></li><li class="breakAll">Rausch ME, Hampilos N, McNeill W, et al. Ectopic Pregnancy. In: Handbook of Obstetric and Gynecologic Emergencies, 5th ed, Benrubi GI (Ed), Lippincott Williams &amp; Wilkins, 2018.</li></ol></div><div id="topicVersionRevision">Topic 5440 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114761" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Injuries to the cervix in sexual assault victims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23376669" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Postcoital bleeding due to cervical endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890095" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cervical endometriosis: clinical character and management experience in a 27-year span.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20085136" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : [Deep cervical endometriosis causing profuse vaginal bleeding. Case report and literature review].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30278229" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Burkitt Lymphoma Presenting as Menorrhagia and a Vaginal Mass in an Adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469290" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469290" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7295606" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Thirty-two years experience in management of primary tumours of the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8798306" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Primary and recurrent colorectal cancer masquerading as gynaecological malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21345435" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18243177" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health Across the Nation (SWAN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24408315" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Is adenomyosis associated with menorrhagia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314908" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17707716" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19185671" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30198563" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30609040" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Corrigendum to "The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions" [Int J Gynecol Obstet 143(2018) 393-408.].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30609040" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Corrigendum to "The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions" [Int J Gynecol Obstet 143(2018) 393-408.].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30306580" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cancer of the corpus uteri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482440" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Frequency of inherited bleeding disorders in women with menorrhagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19236375" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23727521" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275041" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198765" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : von Willebrand disease in women with menorrhagia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292016" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Testing for von Willebrand disease in women with menorrhagia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275228" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27400009" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35983674" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The FIGO ovulatory disorders classification system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22182054" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Menometrorrhagia during the premenopause: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131844" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Disordered folliculogenesis during the menopausal transition: explaining chaos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468195" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: number 41, December 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504731" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Expression of matrix metalloproteinase enzymes in endometrium of women with abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215164" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115504" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Elevated immunoreactivity to tissue factor and its association with dysmenorrhea severity and the amount of menses in adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243126" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17264103" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17430500" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association between Chlamydia trachomatis and abnormal uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18476154" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Performance of clinical and laparoscopic criteria for the diagnosis of upper genital tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816843" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Abnormal vaginal bleeding after epidural steroid injection: a paired observation cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23680518" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cesarean scar defects: an underrecognized cause of abnormal uterine bleeding and other gynecologic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769058" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Preliminary report of treatment with oral contraceptive pills for intermenstrual vaginal bleeding secondary to a cesarean section scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587017" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Saline infusion sonohysterography in nonpregnant women with previous cesarean delivery: the "niche" in the scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15904593" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Surgical treatment and follow-up of women with intermenstrual bleeding due to cesarean section scar defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607033" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cesarean scar dehiscence and irregular uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9952074" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cesarean section scar as a cause of abnormal vaginal bleeding: diagnosis by sonohysterography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23747492" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Finding a niche: Magnetic resonance imaging located an often-overlooked source of uterine bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21031351" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ultrasound evaluation of the Cesarean scar: relation between a niche and postmenstrual spotting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36988956" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Definition and Criteria for Diagnosing Cesarean Scar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31785470" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14605105" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy of embolization in traumatic uterine vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643064" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Arteriovenous malformations of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7860055" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Congenital vascular malformation of the uterus in a stillborn: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11566093" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Uterine artery embolization: the role in obstetrics and gynecology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12053106" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Uterine arteriovenous malformation: ultrasonographic, magnetic resonance and radiological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9423660" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Uterine arteriovenous malformations: gray-scale and Doppler US features with MR imaging correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26873276" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ultrasound diagnosis and management of acquired uterine enhanced myometrial vascularity/arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29124818" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnosis and management of patients with enhanced myometrial vascularity associated with retained products of conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32360145" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sonographic findings after induced medical abortion at 12-21 weeks of gestation: Retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23762732" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Uterine sarcoidosis: a rare extrapulmonary site of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18054922" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dislodged Essure microinsert.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22217630" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706933" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Risk of ovarian cancer in women with symptoms in primary care: population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23613077" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Does this woman have an ectopic pregnancy?: the rational clinical examination systematic review.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
